Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed ...
7d
Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent ...
Dexcom has been hit by a major safety issue for an Android version of its G6 continuous glucose monitoring system app, leading the FDA to issue its most serious recall notice. A “software defect in ...
Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, welcome to the DexCom Third ...
In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global leader in glucose biosensing. As part of the ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
A new store design, though, will be found at Winnipeg’s newest London Drugs location, opening on Nov. 21 in CF Polo Park. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback